Clinical application of multimodal magnetic resonance imaging in glioma

doi:10.3760/cma.j.cn371439-20200529-00101

Abstract

Abstract:

Multimodal magnetic resonance imaging is an emerging brain imaging technology that integrates multiple functions of magnetic resonance imaging technology. It has the advantages of high accuracy, high distinguishability and low invasiveness, and also can provide more comprehensive and systematic brain tissue information in the anatomical, functional and molecular levels. In recent years, with the continuous development of magnetic resonance imaging technology, multimodal magnetic resonance technology has been widely used in the clinical diagnosis and treatment of glioma. Therefore, understanding the principles of multimodal magnetic resonance imaging technology and its application in grading, differential diagnosis and prognostic assessment of glioma can help clinicians make better diagnosis and treatment decisions.

Key words: Magnetic resonance imaging, Glioma, Multimodal imaging

Zhang Wen, Song Qibin, Hu Weiguo. Clinical application of multimodal magnetic resonance imaging in glioma[J]. Journal of International Oncology, 2020, 47(11): 686-690.

References 33

[1]	Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma[J]. Neurosurg Rev, 2017,40(1):1-14. DOI: 10.1007/s10143-016-0709-8. doi: 10.1007/s10143-016-0709-8 pmid: 27085859
[2]	Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016,131(6):803-820. DOI: 10.1007/s00401-016-1545-1. doi: 10.1007/s00401-016-1545-1 pmid: 27157931
[3]	Zhang J, Liu H, Tong H, et al. Clinical applications of contrast-enhanced perfusion MRI techniques in gliomas: recent advances and current challenges[J]. Contrast Media Mol Imaging, 2017,2017:1-27. DOI: 10.1155/2017/7064120.
[4]	Schmainda KM. Diffusion-weighted MRI as a biomarker for treatment response in glioma[J]. CNS Oncol, 2012,1(2):169-180. DOI: 10.2217/cns.12.25. doi: 10.2217/cns.12.25 pmid: 23936625
[5]	Sauwen N, Acou M, Van Cauter S, et al. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI[J]. NeuroImage Clin, 2016,12:753-764. DOI: 10.1016/j.nicl.2016.09.021. doi: 10.1016/j.nicl.2016.09.021 pmid: 27812502
[6]	Svolos P, Kousi E, Kapsalaki E, et al. The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives[J]. Cancer Imaging, 2014,14(1):1-20. DOI: 10.1186/1470-7330-14-20. doi: 10.1186/1470-7330-14-1
[7]	Potgieser AR, Wagemakers M, van Hulzen AL, et al. The role of diffusion tensor imaging in brain tumor surgery: a review of the literature[J]. Clin Neurol Neurosurg, 2014,124:51-58. DOI: 10.1016/j.clineuro.2014.06.009. doi: 10.1016/j.clineuro.2014.06.009 pmid: 25016239
[8]	Ma L, Song ZJ. Differentiation between low-grade and high-grade glioma using combined diffusion tensor imaging metrics[J]. Clin Neurol Neurosurg, 2013,115(12):2489-2495. DOI: 10.1016/j.clineuro.2013.10.003. doi: 10.1016/j.clineuro.2013.10.003 pmid: 24183513
[9]	Xu W, Wang Q, Shao A, et al. The performance of MR perfusion-weighted imaging for the differentiation of high-grade glioma from primary central nervous system lymphoma: a systematic review and meta-analysis[J]. PLoS One, 2017,12(3):e173430. DOI: 10.1371/journal.pone.0173430.
[10]	Boxerman JL, Shiroishi MS, Ellingson BM, et al. Dynamic susceptibility contrast MR imaging in glioma: review of current clinical practice[J]. Magn Reson Imaging Clin N Am, 2016,24(4):649-670. DOI: 10.1016/j.mric.2016.06.005. doi: 10.1016/j.mric.2016.06.005 pmid: 27742108
[11]	Shiroishi MS, Castellazzi G, Boxerman JL, et al. Principles of $T_2^*$-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging [J]. J Magn Reson Imaging, 2015,41(2):296-313. DOI: 10.1002/jmri.24648. doi: 10.1002/jmri.24648 pmid: 24817252
[12]	Chiang GC, Kovanlikaya I, Choi C, et al. Magnetic resonance spectroscopy, positron emission tomography and radiogenomics-relevance to glioma[J]. Front Neurol, 2018,9:33-42. DOI: 10.3389/fneur.2018.00033. doi: 10.3389/fneur.2018.00033 pmid: 29459844
[13]	Aquino D, Gioppo A, Finocchiaro G, et al. MRI in glioma immunotherapy: evidence, pitfalls, and perspectives[J]. J Immunol Res, 2017,2017:1-16. DOI: 10.1155/2017/5813951.
[14]	van Dijken BRJ, van Laar PJ, Holtman GA, et al. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis[J]. Eur Radiol, 2017,27(10):4129-4144. DOI: 10.1007/s00330-017-4789-9. doi: 10.1007/s00330-017-4789-9 pmid: 28332014
[15]	Suh CH, Kim HS, Jung SC, et al. Diffusion-weighted imaging and diffusion tensor imaging for differentiating high-grade glioma from solitary brain metastasis: a systematic review and Meta-analysis[J]. AJNR Am J Neuroradiol, 2018,39(7):1208-1214. DOI: 10.3174/ajnr.A5650. doi: 10.3174/ajnr.A5650 pmid: 29724766
[16]	Jakab A, Molnár P, Emri M, et al. Glioma grade assessment by using histogram analysis of diffusion tensor imaging-derived maps[J]. Neuroradiology, 2011,53(7):483-491. DOI: 10.1007/s00234-010-0769-3. doi: 10.1007/s00234-010-0769-3
[17]	Hilario A, Ramos A, Perez-Nuïez A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the pre-operative grading of diffuse gliomas[J]. AJNR Am J Neuroradiol, 2012,33(4):701-707. DOI: 10.3174/ajnr.A2846. doi: 10.3174/ajnr.A2846 pmid: 22207304
[18]	Giussani C, Poliakov A, Ferri RT, et al. DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma[J]. Neuromage, 2010,52(1):217-223. DOI: 10.1016/j.neuro-image.2010.03.079.
[19]	Nguyen TB, Cron GO, Perdrizet K, et al. Comparison of the diagnostic accuracy of DSC- and dynamic contrast-enhanced MRI in the preoperative grading of astrocytomas[J]. AJNR Am J Neuroradiol, 2015,36(11):2017-2022. DOI: 10.3174/ajnr.A4398. doi: 10.3174/ajnr.A4398 pmid: 26228886
[20]	Cebeci H, Aydin O, Ozturk-Isik E, et al. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method[J]. Eur J Radiol, 2014,83(10):1914-1919. DOI: 10.1016/j.ejrad.2014.07.002. doi: 10.1016/j.ejrad.2014.07.002
[21]	Rapalino O, Ratai EM. Multiparametric imaging analysis: magnetic resonance spectroscopy[J]. Magn Reson Imaging Clin N Am, 2016,24(4):671-686. DOI: 10.1016/j.mric.2016.06.001. doi: 10.1016/j.mric.2016.06.001 pmid: 27742109
[22]	Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis[J]. Int J Radiat Oncol Biol Phys, 2013,87(3):449-457. DOI: 10.1016/j.ijrobp.2013.05.015. doi: 10.1016/j.ijrobp.2013.05.015 pmid: 23790775
[23]	Zhang H, Ma L, Wang Q, et al. Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis[J]. Eur J Radiol, 2014,83(12):2181-2189. DOI: 10.1016/j.ejrad.2014.09.018. doi: 10.1016/j.ejrad.2014.09.018
[24]	Wang S, Martinez-Lage M, Sakai Y, et al. Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI[J]. AJNR Am J Neuroradiol, 2016,37(1):28-36. DOI: 10.3174/ajnr.A4474. doi: 10.3174/ajnr.A4474 pmid: 26450533
[25]	Patel P, Baradaran H, Delgado D, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis[J]. Neur Oncol, 2016,19(1):118-127. DOI: 10.1093/neuonc/now148.
[26]	Muccio CF, Caranci F, D'Arco F, et al. Magnetic resonance features of pyogenic brain abscesses and differential diagnosis using morphological and functional imaging studies: a pictorial essay[J]. J Neuroradiol, 2014,41(3):153-167. DOI: 10.1016/j.neurad.2014.05.004. doi: 10.1016/j.neurad.2014.05.004 pmid: 24957685
[27]	Pal D, Bhattacharyya A, Husain M, et al. In vivo proton MR spectroscopy evaluation of pyogenic brain abscesses: a report of 194 cases[J]. AJNR Am J Neuroradiol, 2010,31(2):360-366. DOI: 10.3174/ajnr.A1835. doi: 10.3174/ajnr.A1835 pmid: 19797788
[28]	Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery[J]. J Neurooncol, 2010,99(1):81-88. DOI: 10.1007/s11060-009-0106-z. doi: 10.1007/s11060-009-0106-z pmid: 20058049
[29]	Blasel S, Jurcoane A, Franz K, et al. Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas[J]. Acta Neurochir, 2010,152(11):1893-1899. DOI: 10.1007/s00701-010-0774-7. doi: 10.1007/s00701-010-0774-7
[30]	Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[J]. Science, 2008,321(5897):1807-1812. DOI: 10.1126/science.1164382. doi: 10.1126/science.1164382 pmid: 18772396
[31]	Thust SC, Hassanein S, Bisdas S, et al. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade Ⅱ/Ⅲ glioma: volumetric segmentation versus two-dimensional region of interest analysis[J]. Eur Radiol, 2018,28(9):3779-3788. DOI: 10.1007/s00330-018-5351-0. doi: 10.1007/s00330-018-5351-0 pmid: 29572636
[32]	Tan WL, Huang WY, Yin B, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases[J]. AJNR Am J Neuroradiol, 2014,35(5):920-927. DOI: 10.3174/ajnr.A3803. doi: 10.3174/ajnr.A3803 pmid: 24557705
[33]	Pope WB, Prins RM, Thomas MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1mutant glioma patients using magnetic resonance spectroscopy[J]. J Neurooncol, 2012,107(1):197-205. DOI: 10.1007/s11060-011-0737-8. doi: 10.1007/s11060-011-0737-8 pmid: 22015945